Company news

Benitec Biopharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

June 25, 2023

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 14, 2023

Benitec Biopharma to Present at the OPMD International Conference

May 7, 2023

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

May 7, 2023

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

February 12, 2023

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

January 22, 2023

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

November 9, 2022

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

September 15, 2022

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

September 11, 2022

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

September 1, 2022

Benitec Biopharma Releases Q3 2022 Financial Results

May 15, 2022

Benitec Biopharma Discloses Q2 2022 Financial Results

February 13, 2022

Benitec Biopharma Discloses Q1 2022 Financial Results

November 14, 2021

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

September 19, 2021

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

September 12, 2021

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

September 7, 2021

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022

September 7, 2021

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

September 7, 2021

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

April 26, 2021

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

April 26, 2021

Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study

February 23, 2021

Benitec Biopharma Announces 2020 Annual Stockholder Meeting

December 6, 2020

Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

October 5, 2020

Benitec Biopharma Announces Pricing of $10.0 Million Public Offering

October 1, 2020

Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results

September 22, 2020

Benitec Biopharma to present at H.C. Wainwright's 22nd Annual Global Investment Conference

August 31, 2020

Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study

July 7, 2020

ASX/NASDAQ ANNOUNCEMENT: Re-domiciliation to the United States

November 26, 2019

Appendix 4C: Quarterly Cash Flow Report

October 30, 2019

Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering

September 29, 2019

Benitec Biopharma to present at Ladenburg Thalmann 2019 Healthcare Conference

September 18, 2019

ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report

July 30, 2019

Update on Oculopharyngeal Muscular Dystrophy Program

June 5, 2019

← Newer news releases

Decks

The 5 newest of 41 decks. Every deck is listed under its year.